1. Catalog
  2. The Lead Episode 154: A Discussion of Safety and E ...
The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead, host Sandeep A. Saha, MD, MS, FHRS, is joined by Babak Nazer, MD, and Rajesh Kabra, MD, FHRS, to discuss the journal article, Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study. Together, they review the study's six-month findings and explore the safety and effectiveness of a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.

  • Review the six-month results of the FlexPulse IDE Study evaluating a dual-energy focal ablation catheter for the treatment of paroxysmal atrial fibrillation.
  • Discuss the safety outcomes reported in the study and their implications for clinical practice.
  • Examine the effectiveness findings of the dual-energy focal ablation approach in patients with paroxysmal atrial fibrillation.

Podcast Contributors

Sandeep A Saha, MD, MS, FHRS 

Babak Nazer, MD

Rajesh Kabra, MD, FHRS

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

S. Saha

• Honoraria/Speaking/Consulting Fee/Speaker’s Bureau: Medtronic, Inc.



B. Nazer

•Honoraria/Speaking/Consulting Fee: Edwards Lifesciences, Biosense Webster, Inc., Siemens Healthineers

•Research: Siemens Healthineers



R. Kabra

•Honoraria/Speaking/Consulting Fee: AtriCure, Inc., Biosense Webster, Inc., Milestone Pharmaceuticals, AltaThera Pharmaceuticals
•Research: Abbott Medical, Medtronic, Inc.


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
E. Downward: No relevant financial relationships with ineligible companies to disclose.